Test Price
2,800 AED✅ Home Collection Available
KIT Gene Piebaldism Genetic Test – NGS Sequencing | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – ISO 9001:2015 accredited next-generation sequencing (NGS) with complete KIT gene coverage, including coding exons, splice sites, and deep intronic regions.
- VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily from 8 AM to 11 PM across all Emirates, performed by DHA-licensed phlebotomists.
- Telephonic Post-Test Clinical Guidance – 15-minute structured consultation with a Consultant Medical Geneticist within 24 hours of report release.
- Direct Insurance Billing – Verify coverage via WhatsApp at +971 54 548 8731.
A definitive molecular diagnostic test for congenital piebaldism, distinguishing it from other pigmentary disorders through comprehensive KIT gene analysis. Results are reviewed and reported by a board-certified consultant medical geneticist under DHA license supervision.
Test Overview & Methodology
The KIT Gene Piebaldism Genetic Test employs next-generation sequencing to analyse the entire KIT gene for pathogenic variants associated with piebaldism – a congenital condition marked by a white forelock and stable depigmented skin patches. This test provides a definitive molecular diagnosis, enabling dermatologists and geneticists to differentiate piebaldism from acquired hypopigmentation disorders such as vitiligo. Comprehensive coverage includes all coding exons, intron-exon boundaries, and selected deep intronic regions, with copy number variant detection for deletions and duplications.
| Feature | KIT NGS Test | Sanger Sequencing |
|---|---|---|
| Method | Next-Generation Sequencing (NGS) – full gene coverage | Single-gene Sanger, limited to known hot-spots |
| Detection Rate | >99% of coding variants, deep intronic, CNVs | ~95% for point mutations in targeted regions |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
| Price (AED) | 2,800 | 1,500–2,000 |
| Specialist Oversight | Consultant Medical Genetics | Laboratory report without clinical interpretation |
Physician Insight & Safety Protocols
"A molecular diagnosis of piebaldism through comprehensive KIT gene sequencing brings clarity to families navigating congenital pigmentary differences. This test offers high diagnostic yield, yet it must be integrated with a thorough clinical evaluation and family history assessment. The result is one component of a complete genetic workup – not a standalone answer. I always counsel patients that a negative result does not exclude all genetic causes and may warrant further investigation."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory: Medication & Clinical Management
Genetic test results provide diagnostic information and should never replace prescribed treatments or regular medical follow-ups. Always consult your treating physician before making any changes to medication or therapy regimens. This test does not assess drug response or adverse reaction risk for any pharmaceutical agent.
Exclusion Criteria & Emergency Red Flags
- Minors (below 18 years): Written informed consent from a legal guardian is mandatory per UAE Federal Law No. 2 of 2019 and PDPL standards. A guardian must accompany the minor during collection.
- Active skin infections or bleeding disorders may contraindicate blood-draw or FTA-card collection – contact our clinical team for pre-booking assessment.
- Post-collection adverse events: If you experience severe allergic reaction, persistent bleeding, vasovagal syncope, or localised infection after sample collection, seek immediate medical attention at the nearest emergency department.
- Emergency red flags: Sudden vision loss, chest pain, difficulty breathing, or signs of anaphylaxis – call 998 immediately.
Patient FAQ & Clinical Guidance
1. What is the KIT Gene Piebaldism Genetic Test?
This test sequences the entire KIT gene using next-generation sequencing to identify pathogenic mutations that cause piebaldism – a congenital disorder characterised by a white forelock and stable depigmented macules. It provides comprehensive analysis of all coding exons, splice sites, and selected regulatory regions, delivering a definitive molecular diagnosis for individuals with congenital hypopigmentation and enabling accurate family counselling.
2. How is the sample collected and what preparation is needed?
Sample collection requires one of the following: a standard peripheral whole blood draw (3–5 mL in an EDTA tube), a pre-extracted DNA sample, or a dried blood spot on an FTA card. No fasting or special preparation is required. A pre-test genetic counselling session to document family pedigree and discuss implications is arranged by our booking team – available virtually or at our Dubai Healthcare City facility. Home collection via VIP mobile phlebotomy is available across all Emirates from 8 AM to 11 PM daily.
3. How should I interpret my results and what are the next steps?
A positive result confirms a pathogenic KIT variant consistent with piebaldism, enabling targeted clinical management, dermatological follow-up, and family cascade testing. A negative result does not exclude all causes of congenital hypopigmentation and may prompt further genetic or dermatologic evaluation. Every report is reviewed by a Consultant Medical Geneticist and includes a 15-minute telephonic post-test counselling session to explain findings, discuss inheritance patterns, and coordinate referrals to specialists as indicated.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
This service complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data are encrypted, access-controlled, and processed exclusively within the UAE. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Laboratory Licensing & Accreditation
DNA Labs UAE operates under DHA Facility License No. 1143 at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. The laboratory holds ISO 9001:2015 certification and follows CAP/CLIA-equivalent quality standards for molecular genetic testing.
Clinical & Logistical Metadata
| Test Name | KIT Gene Piebaldism Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA), Buccal Swab, or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coverage with CNV Detection |
| ICD-10-CM Code | Q82.8, L81.9, Z13.79 |
| LOINC Code | 48018-8 |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians